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Abstract: Creatine is a popular ergogenic aid among athletic populations with consistent evidence
indicating that creatine supplementation also continues to be commonly used among adolescent
populations. In addition, the evidence base supporting the therapeutic benefits of creatine supple‐
mentation for a plethora of clinical applications in both adults and children continues to grow.
Among pediatric populations, a strong rationale exists for creatine to afford therapeutic benefits
pertaining to multiple neuromuscular and metabolic disorders, with preliminary evidence for other
subsets of clinical populations as well. Despite the strong evidence supporting the efficacy and
safety of creatine supplementation among adult populations, less is known as to whether similar
physiological benefits extend to children and adolescent populations, and in particular those ado‐
lescent populations who are regularly participating in high‐intensity exercise training. While lim‐
ited in scope, studies involving creatine supplementation and exercise performance in adolescent
athletes generally report improvements in several ergogenic outcomes with limited evidence of er‐
golytic properties and consistent reports indicating no adverse events associated with supplemen‐
tation. The purpose of this article is to summarize the rationale, prevalence of use, performance
benefits, clinical applications, and safety of creatine use in children and adolescents.
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1. Introduction
Creatine (methyl‐guanidine‐acetic acid) is a naturally occurring amino acid‐like com‐
pound that is endogenously produced within the human body and exogenously con‐
sumed in food sources such as red meat and seafood [1]. Creatine is primarily stored
within skeletal muscle tissue (~95% of total stores) mostly in the form of phosphocreatine,
which functions as an energy source through an enzymatic reaction involving creatine
kinase, phosphocreatine, and adenosine di‐phosphate to yield adenosine tri‐phosphate
(ATP). The inorganic phosphate and free energy yielded from ATP hydrolysis is then
used for cellular work, with increasing demands as the intensity of effort is increased [1].
Research has indicated that internal phosphocreatine stores can be increased by 15–40%
through creatine supplementation strategies, which can subsequently have various per‐
formance‐related benefits in isolation, and when used in conjunction with structured ex‐
ercise training programs over time [2–6]. The purported ergogenic benefits of creatine are
well‐supported within the literature for multiple populations [1]. Because of the strong
evidence for ergogenic benefits pertaining to high‐intensity exercise performance, as well
as an increase in strength and skeletal muscle hypertrophy, creatine is a popular dietary
supplement of choice among athletic populations. A systematic review by Knapik et al.
[7] in 2016 reported creatine use in 50 out of 159 (31%) unique studies examining the prev‐
alence of dietary supplement use by athletes of all ages. Creatine is not only one of the
more popular dietary supplements from a performance perspective, but there is also
strong evidence to support its use in clinical settings for a variety of patient populations
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[1,7]. However, the use of creatine among children and adolescent populations still re‐
mains somewhat controversial. While the physiological rationale regarding an ergogenic
benefit in adolescents is similar to that seen in adults [8], the lack of randomized controlled
trials and clinical data supporting the safety of creatine supplementation protocols among
adolescent populations has resulted in hesitation regarding its widespread recommenda‐
tion by some practitioners. Despite these concerns, creatine is still a popular dietary sup‐
plement of choice among adolescent populations and has been studied for its ergogenic
potential in select athletic populations, albeit mostly in international (non‐US) settings. It
is clear that more research is warranted to better understand the short and long‐term
safety of creatine among adolescent athletes, however there is a precedent for its use
among certain adolescent populations, both in athletes and special populations. There‐
fore, the focus of this article is to summarize the prevalence of use, performance benefits,
clinical applications, and safety of creatine use in adolescents. For the purposes of the cur‐
rent review, children are defined as individuals between the ages of 0–12 years, while
adolescents are defined as individuals between the ages of 13–19 years of age.
2. Effects of Creatine Supplementation on Creatine Content
Although limited in number, select studies have demonstrated that creatine supple‐
mentation is an effective nutritional strategy to promote increases in the phosphocreatine
content and energy status of the cell among pediatric populations [9,10]; however, some
evidence suggests this is potentially so, but to a lesser extent when compared to what is
commonly reported in adult populations [1]. Depending on baseline levels of creatine
content, which tend to be heavily influenced by exogenous creatine intake [11], increases
of 10–40% in creatine or phosphocreatine content within skeletal muscle tissue are rou‐
tinely reported following periods of creatine supplementation in adult populations [1].
Interestingly, preliminary evidence suggests that an age‐dependent effect of creatine sup‐
plementation may exist regarding intramuscular creatine uptake, thereby indicating that
the development of age‐specific supplementation strategies may be warranted [9,10]. Fur‐
ther, research in adult populations [3,12,13] has indicated a moderate degree of variability
in tissue uptake response to creatine supplementation protocols. It is currently unknown
if similar variabilities (i.e., responder vs. nonresponder effects) are also present among
children and adolescents. Due to age and ethical considerations, the majority of research
in pediatric populations has relied on magnetic resonance imaging or laboratory markers
as indirect measures of creatine and phosphocreatine content rather than through muscle
biopsies, which is a common technique used for measuring intramuscular creatine content
in adult populations. Additionally, lower doses of creatine are sometimes used among
pediatric populations, which is also likely to influence the magnitude of changes observed
in creatine content following a supplementation period. Therefore, it is difficult to directly
compare the efficacy of creatine supplementation strategies between age groups when
different techniques are used to quantify creatine content and different dosing strategies
may be employed. However, a study by Solis et al. [10] was able to examine changes in
brain and muscle phosphocreatine content across three age groups (children, n = 15, adult
omnivores, n = 17, adult vegetarians, n = 14, and elderly adults, n = 18) using 31P‐magnetic
resonance spectroscopy, following a standard creatine loading protocol (0.3 g/kg/day for
7 days). Results indicated intramuscular phosphocreatine content significantly increased
by 13.9% while brain phosphocreatine levels only increased by 2.1% among the group of
children [10]. Comparatively, following the same creatine dosing regimen, larger in‐
creases in muscle phosphocreatine content were observed in the elderly (22.7%) but not
adult omnivores (10.3%) when compared to the children. It is also worth noting that lower
baseline levels of muscle phosphocreatine content were observed in the children com‐
pared to the adult groups. Using a lower dose (5 g/day), but over an 8‐week period,
Banerjee et al. [9] reported significantly greater increases in the mean phosphocreatine/in‐
organic phosphate ratio following creatine supplementation compared to placebo (Crea‐
tine: 4.7; 95% CI: 3.9–5.6 vs. Placebo 3.3; 95% CI 2.5–4.2; p = 0.03) in patients with Duchenne
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Muscular Dystrophy. Alternatively, contradictory reports to these outcomes regarding
the efficacy of creatine supplementation have indicated little to no impact on intramuscu‐
lar phosphocreatine content; however the relative dose used in these studies may have
been too low (0.1 g/kg/day for 12 weeks) to elicit any meaningful changes in creatine con‐
tent [12,13]. Additionally, it is also worth noting these studies were conducted in patients
with childhood‐onset systemic lupus erythematosus and juvenile dermatomyositis, which
may have influenced the efficacy of creatine supplementation in its ability to increase
phosphocreatine content. Preliminary evidence among specialized clinical populations
with inborn errors of metabolism, such as creatine deficiencies, has also indicated that
creatine supplementation can positively influence brain creatine content with a subse‐
quent influence on cognition, natural development, and quality of life [14–16]. However,
as highlighted previously by Solis et al. [10], it was reported that a standard creatine load‐
ing regimen (0.3 g/kg/day for 7 days) in prepubescent children, omnivore adults, vegetar‐
ian adults, and elderly adults was not able to elicit significant changes in brain phospho‐
creatine content [10]. Similar findings have also been observed in healthy young children
between the ages of 10 to 12 years of age [17], which failed to observe significant increases
in brain creatine content following creatine supplementation. However, a review by Do‐
lan et al. [18] highlighted multiple studies in adult populations, all of which utilized var‐
ying creatine supplementation strategies (2–20 g per day from 5 days to 8 weeks), that
were able to demonstrate significant increases in brain creatine and phosphocreatine con‐
tent following supplementation. It is possible that higher doses of creatine over longer
periods of time may be required for meaningful increases in brain creatine content to oc‐
cur among healthy populations as has been previously suggested [18]. The potential in‐
crease in brain creatine content following supplementation may also be age‐dependent.
Nevertheless, more research is needed to identify the extent to which creatine supplemen‐
tation can impact brain creatine levels and whether or not modified creatine supplemen‐
tation strategies for this purpose are warranted.
3. Prevalence of Use among Adolescents
The popularity of dietary supplements among adolescent populations has slowly in‐
creased over the past two decades. One of the more popular self‐reported dietary supple‐
ments used among this population is creatine, with evidence of use for performance‐en‐
hancing purposes beginning in the late 1990s [7]. In 2001, when 674 high school athletes
within the United States were surveyed on the use and perceptions of oral creatine sup‐
plementation, results indicated that 75% of athletes were aware of creatine and 16% re‐
ported some level of previous use [19]. Males exhibited much higher (23%) prevalence
rates of use when compared to females (2%), with the percentage of creatine use increas‐
ing with grade level as 5% of 9th grade survey respondents reported creatine use com‐
pared to 22% of those in 12th grade [19]. Interestingly, 97% of athletes indicating creatine
use reported a benefit from creatine, while 26% reported side‐effects, a value that is far
above the typical rate of side‐effects from creatine supplementation within the literature
[1]. It is possible that underlying confusion or bias regarding the side‐effects of creatine
supplementation influenced the high rate of side‐effects reported in this study. Neverthe‐
less, a more in‐depth discussion regarding adverse events and the safety of creatine sup‐
plementation can be found later in the review in section 6. Nearly 70% of creatine users
reported ingesting a loading dose (i.e., 5–10 g for a period of 3–5 days) and nearly all
creatine users reported the use of a maintenance dose following the loading period. In
2002, 16.7% of 4011 high school student‐athletes surveyed from the United States self‐re‐
ported current or prior creatine use with a higher use rate among males (25.3%) compared
to females (3.9%) [20]. Additionally, the authors noted a large range of creatine use across
sport‐type, with football representing the highest (30.1%) rates of use and female cross‐
country representing the lowest (1.3%) rates of use. Increased strength was indicated as
the most common reason for creatine supplementation. In 2004, among a convenience
sample of 333 adolescents in a Midwestern Canadian province, 5.3% of those surveyed
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self‐reported prior creatine use with 6.6% self‐reporting they would use creatine in the
future [21]. Individuals who self‐reported current creatine use spent more time being
physically active throughout the week compared with those not reporting creatine use.
Additionally, among this population a higher rate of use was observed in males compared
to females, which is in accordance with previous findings. Interestingly, 43.1% of athletes
did not know if creatine would enhance performance while 14.2% believed that it would
not improve performance, which highlights the need for improved education in this area.
Shortly thereafter, in 2008, Hoffman et al. [22] surveyed a group of 3248 students in grades
8–12 within the United States and found 7% of survey respondents self‐reported creatine
use. Boys reported greater use of creatine with progressively increasing rates of creatine
use reported at higher grade levels (22% of 12th grade boys). When asked about their
primary source of information regarding dietary supplements, teachers (36%) and parents
(16%) were the most common responses among all students. In 2012, results from a large
subset (n = 9417) of the National Health Interview Survey respondents indicated that
34.1% of the children or adolescents (mean age = ~11 years) reporting the use of dietary
supplements to enhance sports performance, self‐reported using creatine [23]. Most re‐
cently, in 2020 among a sample of Australian adolescent boys participating in a variety of
sports, 8.4% of survey respondents reported current use of creatine and 25.7% reported
the intent to use creatine or other dietary supplements in the near future [24]. Drive for
muscularity, participating in weight training, and sport participation were strong predic‐
tors of supplement use [24]. It is important to note that there is an underlying concern that
creatine use among adolescents may be a predictor of future illegal performance enhanc‐
ing substance use. However, the survey utilized to examine this relationship [25], inap‐
propriately categorized creatine as an androgenic anabolic agent, rather than an amino‐
acid compound, thereby introducing bias to the future projection and therefore caution
should be used when interpreting these findings.
The prevalence of creatine use tends to be higher among international adolescent
athletes competing at the elite level. For example, Petroczi et al. [26] surveyed elite ado‐
lescent athletes as part of the United Kingdom Sport 2005 Drug Free Survey and when a
subsample of 874 athletes were reanalyzed, 36.1% of athletes reported using creatine. Of
note, a strong relationship was present between reasons for creatine use and physiological
rationale among creatine users. This relationship indicates that those self‐reporting crea‐
tine use were able to correctly identify the purported benefits while selecting physiologi‐
cally appropriate reasons for use, which was not observed for other dietary supplements.
Similarly, in 2008 Petroczi and Naughton [27] surveyed a cohort of 403 elite athletes from
the United Kingdom and reported 28% of athletes self‐reported creatine use. More re‐
cently in 2019, Jovanov et al. [28] surveyed 348 male and female adolescent athletes across
four different countries who were all competing at an international level for their respec‐
tive countries and reported that 25.3% of all athletes indicated using creatine. In alignment
with previous studies, a significantly higher proportion of male athletes reported using
creatine compared to female athletes (72.0% vs. 28.0%). Additionally, a higher proportion
of athletes in the 17–18 year old age group reported creatine use, compared to the 15–16
year old group (60.0% vs. 40.0%). It is important to highlight these findings as they are
some of the highest creatine use rates reported among a cohort of adolescents, which may
be an indication of recent trends for higher creatine use. These outcomes may also be at‐
tributed to the continued growth of the dietary supplement market, popularity of com‐
petitive youth sports at an elite level, and the increasing reputation of creatine’s ergogenic
properties. It is also important to note that there has been a significant increase in the
prevalence of creatine supplementation among female athletes, in particular, over the past
20 years [19,28]. While creatine appears to be a popular dietary supplement of choice
among elite adolescent athletes, creatine is still less frequently used when compared to
other dietary supplement categories such as multivitamins, protein powders, and energy
products, in which usage rates of these product categories can range anywhere from 60–
80% among adolescent athletes [26–32]. More research is needed to better understand the
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contextual factors underpinning these trends in dietary supplement use among adoles‐
cents.
4. Performance Benefits
When compared to adults, a limited number of controlled investigations examining
the ability of creatine supplementation to impact measures of exercise performance
among adolescent populations exist. All available studies to date, have been completed in
only two types of athletes: swimming (n = 5) and soccer (n = 4). Additionally, studies were
completed across all parts of the globe with two studies being completed in Brazil and
one study being completed in Hungary, Australia, USA, United Kingdom, Iran, and Yu‐
goslavia. The studies completed on swimmers differed somewhat in the dosing regimen
that was employed. Three of the studies utilized a loading phase for the entirety of the
supplementation regimen, incorporating doses of 21 g per day for nine days, 20 g per day
for five days, and 20 g per day for 4 days [33–35]. The other two studies used a combina‐
tion of a loading (5 days at 20 g/day or four days at 25 g/day) and a maintenance phase (5
g/day for 22 days or 5 g/day for 2 months) [36,37]. Various parameters of swimming per‐
formance were assessed ranging from in‐water sprint swimming performance to power
outputs completed during a swim bench/ergometer test. All studies that reported out‐
comes within the initial 4–9 days of supplementation identified an improvement in vari‐
ous performance measures such as swim bench test performance, sprint swimming per‐
formance, dynamic strength, and anaerobic exercise performance. The longest study by
Theodorou et al. [37], reported improvements in interval swimming exercise performance
after the loading phase, but no further improvement after a maintenance dose was admin‐
istered. Alternatively, Dawson et al. [36] reported improvements in swim bench perfor‐
mance, but not sprint swimming performance after completion of both a loading and
maintenance phase. While not directly performance related, Juhasz et al. [38] indicated
that creatine supplementation may also be an effective strategy to support the rehabilita‐
tion of overuse‐associated tendinitis in adolescent swimmers when combined with a tar‐
geted physical therapy program. Notably, when indicated by the authors, no adverse
events were reported in any of these studies.
The studies that enrolled adolescent soccer athletes as study participants ranged in
duration from 7–49 days. Three studies were seven days in duration and employed load‐
ing phases that each delivered different loading doses (0.03 g/kg/day, 20 g/day, and
30 g/day) [39–41]. One study [42] was seven weeks in duration and used a seven‐day load‐
ing phase (20 g/day) followed by a six‐week maintenance dose of 5 g/day. All studies were
placebo‐controlled. Of interest, all three studies that were <7 days in duration, reported
statistically significant improvements in various performance outcomes. For example,
Mohebbi et al. [39] reported a significant improvement in repeat sprinting and soccer drib‐
bling performance, while Ostojic et al. [40] reported improvements in performance of a
soccer dribbling test, countermovement jump, and power production during a sprint.
Lastly, Yanez‐Silva et al. [41] reported improvements in peak and mean power output as
well as total work completed during a Wingate anaerobic capacity test. The remaining
study, Claudino et al. [42] failed to report any improvements in lower body power pro‐
duction after 14 male adolescent soccer athletes completed a one‐week loading and a six‐
week maintenance dose phase. Finally, and similar to what was observed with the studies
involving swimming, creatine was well tolerated with no adverse events being reported.
A summary table of these studies has been included in Table 1.
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Table 1. Efficacy of creatine use in adolescents on exercise performance.
Author Year
(Country)

Subjects

Design

Duration Dosing Protocol Primary Variables

Results

Adverse
Events

Swimming
10 male,
Dawson et al.
10 female
Matched, placebo‐
2002
4 weeks
(16.4 ± 1.8
controlled
(Australia)
years)
[36]
swimmers
18 (11 female,
Randomized,
Grindstaff et 7 male) ado‐
lescent swim‐ double‐blind,
9 days
al. 1997
(USA) [33] mers (15.3 ± placebo controlled
0.6 years)
Juhasz et al.
16 male
Randomized,
2009
fin swimmers
placebo‐controlled, 5 days
(Hungary)
(15.9 ± 1.6
single‐blind trail
[34]
years)
10 elite fe‐
male (17.7 ±
Theodorou et 2.0 years) and Randomized,
12 elite male
al. 1999
double‐blind,
11 weeks
(UK) [37]
(17.7 ± 2.3 placebo‐controlled
years) swim‐
mers
10 high per‐
formance
Theodorou et
swimmers
al. 2005
Randomized,
(males: n = 6;
4 days
(United
double‐blind trial
females: n = 4)
Kingtom) [35]
(17.8 ± 1.8
years

20 g/day (5 days)
5 g/day (22 days)

21 g/day

Sprint swim per‐
↑ swim bench test
None reported
formance and
performance
swim bench test
Sprint swim per‐
formance; arm er‐
gometer perfor‐
mance

↑ sprint swim‐
ming perfor‐
mance

None reported

↑ anaerobic per‐
formance;
None reported
20 g/day
↑ dynamic
strength
↑ interval perfor‐
mance following
loading phase;
25 g/day (4 days) Swimming interval
↔ long‐term im‐ None reported
5 g/day (2 months)
performance
provements after
maintenance
dose
Average power,
dynamic strength
(swim based tests)

↑ mean swim ve‐
Gastrointestinal
locity for all
20 g/day of CrM or High‐intensity
discomfort in
swimmers;
20 g/day of CrM + swim performance
CrM + Carbo‐
100 g of carbohy‐ during repeated ↔ swim velocity
hydrate group
intervals
drates per serving
in Cr + Carbohy‐
only
drate condition
Soccer

14 male Bra‐
Randomized,
Claudino et zilian elite
7 weeks
soccer players double‐blind,
al. 2014
(18.3 ± 0.9 placebo‐controlled
(Brazil) [42]
years)

Lower limb muscle
20 g/day (1 week) power via counter‐ ↔ lower body
None reported
5 g/day (6 weeks) movement vertical
power
jump

17 adolescent
Randomized,
Mohebbi et
soccer players
double‐blind,
al. 2012
(17.2 ± 1.4
placebo‐controlled
(Iran) [39]
years)

7 days

20 g/day

Ostojic et al. 20 adolescent
male soccer Matched, placebo‐
2004
(Yugoslavia) players (16.6
controlled
[40]
± 1.9 years)

7 days

30 g/day

Elite youth
Matched,
Yanez‐Silva et
soccer players
double‐blind,
al. 2017
(17.0 ± 0.5
(Brazil) [41]
placebo‐controlled
years)

7 days

0.03 g/kg/day

Repeated sprint
↑ repeat sprint
test,
performance;
None reported
soccer dribbling
↑ dribbling per‐
performance and
formance
shooting accuracy
↑ dribble test and
endurance times;
Soccer specific
↑ sprint power None reported
skills tests
test and counter‐
movement jump
Muscle power
output
↑ peak and mean
(Wingate
power output; None reported
anaerobic power
↑ total work
test)

↔ = Creatine supplementation resulted in no significant (p > 0.05) change; ↑= Creatine supplementation resulted in a significant increase
(p < 0.05) over control. CrM = creatine monohydrate; g/day = grams per day. Adapted from Jagim et al. 2018 [43].
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In summary, limited research is available that has examined the potential of creatine
supplementation to impact various aspects of exercise performance. Of the limited work
that has been completed, creatine appears to be well‐tolerated with no adverse events be‐
ing reported and consistent improvements in assessments associated with swimming and
soccer performance observed in adolescent athletes. Future research is warranted to better
evaluate the ability of creatine to influence other types of exercise performance and sport‐
specific activities as well as the potential for synergistic adaptations to exercise training.
Moreover, additional research is urgently needed in adolescent females across all sport
types and while research is welcomed in swimming and soccer, future research should
examine the potential of creatine in other popular team‐based sports where strength and
power are key physiological attributes in predicting sporting success.
5. Clinical Applications
Over the past 30 years, the discovery of inborn errors of metabolism and the potential
physiological, neurological, and neuroprotective benefits of creatine have led to advance‐
ments in the therapeutic use of creatine. As such, several pediatric clinical populations
have been shown to benefit from creatine supplementation, which notably includes pa‐
tients with genetic defects associated with creatine deficiency. Table 2 presents a summary
of studies that have examined the therapeutic benefits of creatine supplementation for a
variety of clinical disorders. To date, the majority of clinical trials investigating the thera‐
peutic potential of creatine supplementation in pediatric populations have focused on cre‐
atine (and/or creatine transporter) deficiencies, inborn errors of metabolism, neuromus‐
cular disorders, and myopathies [9,44–49]. Guanidinoacetate methyltransferase (GAMT)
and arginine:glycine amidinotransferase (AGAT) deficiency, are types of inborn errors of
creatine metabolism, collectively characterized as cerebral creatine synthesis deficiencies
[47,50]. Several studies and case reports have indicated that creatine supplementation can
restore tissue creatine content and improve some of the symptoms resulting from creatine
deficiencies [51–54]. Since its discovery in 1994, GAMT deficiency has shown to be treata‐
ble through creatine supplementation strategies [51,53]. For example, in 1996, Stockler et
al. [54] treated an infant patient with GAMT deficiency using a creatine replacement ther‐
apy of 4–8 g/day over a 25‐month period and reported substantial clinical improvement,
normalization of brain MRI abnormalities, and improvements in electroencephalogram
readings post‐treatment. Since that time, several additional case reports and reviews have
been published, highlighting effective strategies to diagnose and treat cerebral creatine
deficiency with consistent improvements in intellectual development reported, especially
when early detection and ensuing treatment were employed [51,52]. While similar in na‐
ture, AGAT deficiency is extremely rare with only 20 documented cases worldwide [52].
AGAT deficiency is also an autosomal recessive disorder that disrupts the biosynthesis of
creatine and is associated with a variety of clinical features such as intellectual develop‐
ment disorder, speech delays, autistics behaviors, and occasional seizures [52]. Thank‐
fully, AGAT also appears to betreatable with creatine supplementation. For example,
Ndika et al. [14] treated a 9‐year‐old female pediatric patient with AGAT deficiency with
up to 800 mg/kg/day of creatine over an 8‐year period and reported partial recovery of
cerebral creatine levels with the patient demonstrating superior nonverbal and academic
abilities at age 9, compared to initially presenting with a score of 43% of her chronological
age at 16 months when assessed using the Bayley’s Infant Development Scale. Although
similar, creatine transporter deficiency is another inborn error of metabolism that can re‐
sult in creatine deficiencies in select tissues, particularly within the brain [51]. Creatine
transporters are membrane‐bound transport proteins that have been found in a variety of
different tissues and are required for tissue uptake of creatine against its concentration
gradient. Moreover, creatine transporter 1 (CrT1) is expressed ubiquitously across human
tissues and deficiencies of this protein are another type of creatine metabolism disorder
that can result in brain atrophy, intellectual disabilities, and developmental delays [51].
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However, this defect is not as responsive to exogenous creatine supplementation strate‐
gies, as the deficiency is attributable to an inability to transport creatine across the cell
membrane, rather than a lack of creatine availability [47]. As such, current research has
focused on identifying alternative strategies that may enhance brain creatine content in
these populations. For example, recent work has demonstrated early promise with the use
of creatine fatty esters and lipid nanocapsules as a nutrition‐based therapeutic treatment
for creatine transporter deficiency [55,56]. These creatine esters and lipid based nanocap‐
sules are better able to cross the blood−brain barrier, thereby helping to increase brain
creatine content and correct the creatine deficiency [56].
Table 2. Efficacy of creatine in clinical settings.
Author Year

Sipila et al.
1981[57]

Subjects

Design

Duration

7 (3 adolescents)
Open label
patients with gy‐
treatment in‐ 12 months
rate atrophy of
tervention
retina

13 patients (9
male, 4 female)
between ages of Prospective,
Vannas‐Sulonen
6–31 years diag‐ open‐label co‐
et al. 1985 [58]
hort
nosed with gy‐
rate atrophy of
the choroid

36–72
months

36 patients with
multiple types of
muscular dystro‐
Randomized,
phies (overall
double‐blind,
Walter et al. 2000
mean age: 26 ± 16
placebo‐con‐
[59]
years) 8 patients
trolled
with Duchenne
dystrophy (mean
age: 10 ± 3 years)

8 weeks

Supple‐
mented for
18 cystic fibrosis
Prospective
12 weeks;
Braegger et al. patients (7 F, 11
open‐label pi‐
monitored
2003 [60]
M) ranging in age
lot
for 24–36
from 8–18 years
weeks

Double‐blind,
15 boys with
3 months,
placebo‐con‐
Louis et al. 2003 muscular dystro‐
with 2
trolled, cross‐
[61]
phy (mean age:
months
over study
10.8 ± 2.8 years)
washout
design

30 boys with Du‐
Double‐blind,
Tarnopolsky et chenne muscular
randomized, 4 months
al. 2004 [45] dystrophy; mean
crossover trial
age: 10 ± 3 years;

Dosing Protocol Primary Variables

Results

Adverse
Events

Visual acuity, mus‐ ↔ Visual acu‐
cle fiber character‐
ity;
No side effects
1.5 g/day
istics, laboratory ↑Thickness of
reported
markers of creatine Type II muscle
metabolism
fibers
↔ Cr supple‐
mentation did
not prevent
Morphological and
0.25–0.5 g dose
normal deterio‐
eye function as‐
None reported
3×/day
ration;
sessments
↓ Muscle atro‐
phy, primarily
in type II fibers
↑ (3%) in mus‐
cle strength;
Muscular perfor‐ ↑ (10%) in neu‐
mance, neuromus‐ rological symp‐
None reported.
10 g/day (adults)
toms.
cular symptoms
Indicated to be
5 g/day (chil‐
Children
score, vital capac‐
well‐tolerated.
dren)
ity and qualitative tended to expe‐
rience greater
assessments
strength
changes.
↔ Lung func‐
One patient ex‐
12 g/day for 1st
tion or sweat
Lung function,
perienced tran‐
week; 6 g/day for
electrolytes.
strength, and clini‐
sient muscle
remaining 11
↑ (18%) in peak
cal parameters
pain; No other
weeks
isometric
side effects
strength
↑ MVC by 15%
↑ TTE (~2×)
Muscle function,
↑ TJS
densitometry,
↑ LS and WB
No changes in
markers of hepatic
BMD in ambu‐
3 g/day
and renal function,
liver or kidney
latory patients
magnetic reso‐
markers
↑ NTx/creati‐
nance spectros‐
nine ratio in
copy
ambulatory pa‐
tients
↑ handgrip
Pulmonary func‐
strength, fat‐
tion, strength,
0.10 g/kg/day
None
body composition, free mass, and
bone health, task bone markers
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height: 129.2 ±
16.0 cm; weight:
35.3 ± 15.8 kg

Escolar et al.
2005 [49]

function, blood & ↔ functional
urinary markers tasks or activi‐
ties of daily liv‐
ing

50 ambulatory
steroid naïve Double‐blind,
boys with Du‐ placebo‐con‐
6 months
chenne Muscular trolled, ran‐
Dystrophy (mean domized
age: 6 years)

39 children/ado‐
Sakellaris et al. lescents following Open‐label
2008 [62]
traumatic brain pilot study
injury
9 children with
lymphoblastic
leukemia during
Cross sec‐
chemotherapy (in
Bourgeois et al.
tional, mixed
treatment group);
2008 [63]
cohort de‐
mean age of 7.6
signs
years, 50 healthy
children as his‐
tory controls
33 ambulatory
Randomized,
male patients
Banerjee et al.
placebo‐con‐
with Duchenne
trolled, sin‐
2010 [9]
muscular dystro‐
gle‐blind trial
phy

6 months

16 weeks

8 weeks

5 g/day of crea‐ Manual muscle
↔ primary or
performance,
tine powder, 0.3
secondary out‐
mg/kg of gluta‐ quantitative mus‐
comes
mine (×2 per cle testing, time to
measures
rise
day), or placebo

0.4 g/kg/day

0.1 g/kg/day

Duration of amne‐
↓ Amnesia
sia, duration of in‐
↓ Intubation
tubation, and in‐
period
tensive care unit
↓ Intensive care
stay post traumatic
unit stay
brain injury

Deemed safe
and well‐toler‐
ated with no
side effects re‐
ported.

None

Height, weight,
BMI, BMD, BMC,
↑ %BF and BMI None reported
FFM, %BF, serum
creatinine

Cellular energetics,
Cr, 5 g/day (n = manual muscle test ↑ in PCr/Pi ra‐
None reported
18)
score and func‐
tios
tional status

Initial ↑ in loco‐
motor and per‐
Cr (400
Locomotor and sonal social IQ No adverse
9 boys with crea‐ Long‐term
Van de Kamp et
mg/kg/day) and
personal social IQ subscales; No events were re‐
tine transporter follow‐up in‐ 4–6 years
al. 2012 [16]
L‐arginine (400
lasting clinical
subscales
defect
vestigation
ported.
mg/kg/day)
improvement
was recorded
↔ intramuscu‐
Muscle function, lar PCr, muscle
body composition, function, and ↔ laboratory
15 participants Double‐blind, 12 weeks
biochemical mark‐ aerobic condi‐ parameters; No
Hyashi et al.
with childhood placebo con‐ with 8 week
0.1 g/kg/day
ers of bone, aerobic tioning param‐ side effects re‐
2014 [13]
systemic lupus trolled, cross‐ washout pe‐
conditioning, qual‐ eters, body
erythematosus over design
riod
ported
ity of life
composition,
quality of life
Primary: muscle
function
Secondary: body
↔ Muscle
composition, bio‐
Randomized,
function, intra‐ No side efforts
Patients with ju‐
chemical markers
reported.
double‐blind,
muscular PCr
Solis et al. 2016 venile derma‐
of bone remodel‐
placebo‐con‐ 12 weeks
0.1 g/kg/day
content, or ↔ Markers of
[12]
tomyositis (mean
ing, cytokines, la‐
trolled, cross‐
other second‐ kidney func‐
age: 13 ± 4 years)
boratory markers
over trial
ary outcomes
tion
of kidney function,
measures
aerobic condition‐
ing, and quality of
life
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22 children (9 F,
None reported,
6/22 (27%) re‐
13 M) with refrac‐
well‐tolerated
0.4 g/kg/day cre‐ Proportion of re‐ sponded to cre‐
Prospective 3–12 months
with no exacer‐
Kalamitsou et al. tory epilepsy
atine + ketogenic sponders to keto‐ atine addition
cohort
follow‐up
ranging in age
bations of un‐
2019 [64]
diet
genic diet
to ketogenic
from 10 months
derlying pa‐
diet
to 8 years
thology
↔ in muscle
13 (7 F, 6 M) pa‐
function,
Safety and tolera‐
tients ranging in
strength, aero‐
Up to 40 kg was
bility
Randomized,
age from 7–14
bic capacity, fa‐
No adverse
Dover et al. 2020
150 mg/kg/day muscle function,
double‐blind,
years with juve‐
6 months
tigue, physical
events reported
[65]
>40 kg was 4.69 disease activity,
placebo‐con‐
nile dermatomyo‐
activity
g/m2/day
aerobic capacity,
trolled
sitis; 25.6–64.6 kg;
↓ in muscle pH
muscle strength
14.3–22.9 kg/m2
following exer‐
cise
↑= Creatine supplementation resulted in an increase in the target outcome; ↓ = Creatine supplementation resulted in a decrease (direc‐
tional) in the target outcome. BMI = body mass index; FFM = fat‐free mass; %BF = body fat percentage; TJS = total joint stiffness; TTE =
time to exhaustion; g/d = grams per day; g/kg/d = grams per kilogram of bodyweight per day; mg/kg/d = milligrams per kilogram of
bodyweight per day; PCr = phosphocreatine. MVC = maximum voluntary contraction; NTx = N‐terminal telopeptide of type I collagen;
LS = lumbar spine; WB = whole body; BMD = bone mineral density; BMC = bone mineral content; Pi = inorganic phosphate.

Considerable research has also been dedicated to investigating the therapeutic bene‐
fit of creatine in the management of myopathies. As a high percentage of creatine is stored
within skeletal muscle tissue, muscle disorder pathologies, such as myopathies, are often
associated with reduced intramuscular concentrations of creatine, phosphocreatine, and
ATP in addition to subsequent neuromuscular impairments and muscle weakness [66].
As such, a strong underlying physiological rationale exists to support the potential of cre‐
atine supplementation as a therapeutic agent in the management of myopathies. For ex‐
ample, Duchenne’s muscular dystrophy is one such myopathy that is progressive in na‐
ture with no known cure. Patients are often prescribed corticosteroids to slow disease pro‐
gression, which can have several adverse side effects when used long‐term. Because of the
catabolic nature of corticosteroid therapy, and musculoskeletal pathology associated with
muscular dystrophy, creatine supplementation has been identified as a therapeutic agent
to potentially counteract the deleterious effects of both the disease, and comorbidities
which arise secondary to the primary corticosteroid treatment. Favorable improvements
have been observed for fat‐free mass and strength in pediatric patients [45]. A major chal‐
lenge with clinical trials investigating the therapeutic benefits of creatine supplementation
in patients with various types of myopathies is dealing with the heterogeneity of the dis‐
ease itself. The diversity in how the disease manifests in patients can subsequently influ‐
ence the time course of disease progression and individualistic nature of active versus
remission disease states, all of which can be difficult to account for with an optimal study
design.
Gyrate atrophy of the retina and choroid is another creatine deficiency disorder that
is characterized as an enzymatic disorder attributable to defects in ornithine aminotrans‐
ferase, resulting in elevated levels of ornithine, which negatively impacts creatine synthe‐
sis [57,67]. As a result, creatine concentrations in serum, urine, erythrocytes, brain, and
muscle are reduced in these patient populations [58,67]. These patients present primarily
with eyesight problems beginning as early as age five, which progressively deteriorate
over time. Results from studies spanning up to 72 months in this patient population indi‐
cate that creatine supplementation can slow disease progression while also helping to
maintain levels of type II skeletal muscle fiber content [68,69].
Lower amounts of daily exogenous creatine intake have also been associated with
depression in young adult populations as Bakian et al. [70] observed a significantly higher
prevalence of depression (10.2/100 persons) in the lowest quartile of dietary creatine in‐
take compared to the highest quartile of creatine intake, which had a depression preva‐
lence rate of 6.0/100 persons. This relationship appeared to be strongest in females and
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those in the 20–39 years of age category and therefore may also extend to adolescents.
Additionally, early evidence indicates that creatine may be used as an adjunctive therapy
in the actual management of clinical depression [71–73]. Creatine supplementation has
also been used as an experimental therapeutic agent for conditions pertaining to hypoxia
and energy‐related brain pathologies such as traumatic brain injuries or cerebral ischemia
in pediatric patients [20,49,74]. There has also been recent interest in examining the poten‐
tial benefits of creatine supplementation for pregnant women with potential benefits ex‐
tending to the developing fetus [75,76]. Currently, clinical trials are underway to better
understand how creatine may affect both the mother and developing fetus [75]. It is also
worth noting that a growing body of evidence exists demonstrating that creatine may also
confer a variety of physiological benefits for multiple clinical conditions in adult popula‐
tions, such as mitochondrial disease, neurological disorders, and autoimmune disorders
[47,74], but the extent to which these findings may extend to pediatric populations re‐
quires more research due to the limited data currently available. Lastly, and a point that
is beyond the scope of this review, all of these findings may hold particular importance
for any clinical population (adult or adolescent) who are vegetarians as they may be sus‐
ceptible to low daily creatine intake through diet alone, as has been reported in adults
[3,11,61].
6. Safety
An extensive summary highlighting the safety of creatine supplementation was re‐
cently addressed in a 2017 Position Stand by Kreider et al. [1]. However, to date, all pub‐
lished studies involving an a priori research question and utilizing a study designed to
examine the safety of creatine supplementation have thus far only been completed in adult
populations. Currently, no studies have been published examining safety considerations
in healthy young or adolescent athletic populations. Importantly and practically speaking,
no indications currently exist as to why a similar safety profile would not be observed in
adolescents, and as highlighted throughout the previous sections, multiple creatine sup‐
plementation studies have been conducted in adolescent athlete and clinical populations
with no adverse events reported. Several of these studies have even closely monitored
laboratory markers throughout the supplementation period with no indications of clini‐
cally relevant adverse effects observed. While the authors agree, and would like to pub‐
licly state that an absence of self‐reported adverse events by study subjects is not a confir‐
mation of safety, it does support the hypothesis that creatine is likely safe for this popula‐
tion. Nonetheless, safety studies in youth and adolescent populations using randomized
controlled trial designs are desperately needed to help continue building the safety profile
for creatine supplementation among these younger age groups. Another way to assess
safety‐related concerns is to examine adverse event reports that are submitted to the Cen‐
ter for Adverse Event Reports, which is overseen by the Center for Food Safety and Ap‐
plied Nutrition as part of the United States Food and Drug Administration (FDA). When
searching this adverse event reporting system database, which is publicly available, only
22 out of the 15,274 (0.144%) adverse events reports were associated with creatine during
the 2018–2020 reporting period, after filtering out food, cosmetics, and adverse events
without a known product code (Accessed 2/5/2021; file dates January 2018–March 2020)
[77]. In perhaps the strongest testament to the safety of creatine, the United States FDA
recently designated creatine as “generally recognized as safe” (GRAS)
(https://www.fda.gov/media/143525/download) [78]. Ultimately, this classification indi‐
cates that creatine is considered safe under the conditions of its intended use based on the
currently available scientific evidence as decided upon by a panel of qualified content
experts. Importantly, and a point that is pertinent to the topic of the current article, this
designation of safety extends to older children and adolescents.
A unique 2019 study published by Simpson and colleagues [79] may provide some
of the first published data involving youth athletes following creatine supplementation
with outcomes pertaining to safety implications, and adverse events. In this study 19 elite
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soccer players (n = 13, U18 “Under 18 years” and n = 6, U21 “Under 21 years”) completed
an eight‐week supplementation regimen of creatine monohydrate (0.3 g/kg/day for 7 days
and 5 g/day for the remaining seven weeks) in a randomized, double‐blind, placebo‐con‐
trolled fashion. Before and after supplementation, study participants had airway inflam‐
mation (using exhaled nitric oxide) and airway responsiveness to dry air (hyperpnea) as‐
sessed before and after supplementation. Participants with previous pulmonary disease
were excluded and all participants were assessed for unknown or undiagnosed allergies
prior to the study. A statistically meaningful trend (p = 0.056) between the groups with
medium to large observed effect sizes (n = 0.199) were found regarding the amount of
exhaled nitric oxide (an assessment of airway inflammation). There was also as a trend (p
= 0.070, n = 0.975) of forced expired volumes in one second to reduce with creatine sup‐
plementation when compared to placebo. The authors concluded that, “we cannot exclude
that creatine supplementation has an adverse effect of the airways of elite athletes, partic‐
ularly in those with allergy sensitization.” These isolated and initial findings are some of
the first published data to suggest that creatine supplementation may compromise airway
health and thus more research is needed to confirm or refute these findings.
7. Practical Recommendations and Future Directions
In conclusion, there appears to be strong evidence of creatine use among adolescents,
particularly among male athletes with the highest usage rates evident among interna‐
tional adolescent athletes competing at the elite level. The majority of adolescents who
self‐report using creatine, appear to get their information from friends, coaches, and par‐
ents. However, the need for replication of dietary supplement questionnaire studies con‐
tinues to be present because of the recent growth in the dietary supplement industry. Ad‐
ditionally, the recent popularity of marketing through social media platforms and online
markets for supplement companies has likely altered how adolescents perceive and obtain
information surrounding dietary supplements in addition to how they purchase them.
Further, there continues to be a need for more education regarding safe and effective die‐
tary supplement strategies among adolescents, rather than strict policies avoiding or ad‐
vocating against their use. Even young adults pursuing careers in health professions do
not appear to have sufficient knowledge of the safety, regulation, and efficacy of various
dietary supplements [80], which reinforces the need for more education and dialogue sur‐
rounding the topic, particularly when one considers the high prevalence of use across all
populations.
A small number of investigations have reported on the ergogenic benefits of creatine
supplementation in adolescent athletes (Table 1), with the majority of this data being pub‐
lished in international (non‐US) adolescent males competing in swimming or soccer.
However, a paucity of observational and no experimental research exists that examines
changes in the clinical health markers among healthy adolescents who are supplementing
with creatine, especially those who regularly partake in high‐intensity exercise training
and athletic competition. While data is limited, it is not entirely absent as many studies
report on the lack of reported side‐effects, nonsignificant changes in laboratory markers
of kidney and liver function, and a lack of changes in inflammatory cytokines among clin‐
ical populations, therein supporting the hypothesis that creatine supplementation is likely
safe for an adolescent population. The lack of adverse event reports in the literature
among clinical populations is telling, particularly when considering that several of the
patients are on immunosuppressive therapies or have multiple comorbidities that could
negatively influence various indictors of health status. Regardless, a dire need exists for
prospective randomized, double‐blind, placebo‐controlled trials examining the safety and
efficacy of creatine among children and adolescent populations; both among athletes and
the general population. Equally important are well‐powered, randomly controlled trials
examining the status and changes in body water and cellular hydration status before,
throughout, and after standard regimens of creatine supplementation and to what extent
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these changes impact creatine content, performance and physiological adaptations to reg‐
ular exercise training. Priority should first be placed on examining the effects of various
creatine‐dosing strategies on markers of clinical health or any contraindications for use
among this population. From there, emphasis should be placed on continuing to explore
the potential benefits of creatine among clinical populations where there might be a
unique physiological rationale for a therapeutic benefit of creatine. These conditions may
include myopathies, muscular dystrophy, muscle wasting conditions, cancer cachexia,
clinical depression, traumatic brain injuries, spinal cord injuries, orthopedic injuries, and
periods of bed rest or immobilization. Lastly, several of the previously published studies
which examined physical performance outcomes in healthy adult populations should be
replicated in adolescents to examine if similar ergogenic benefits from creatine supple‐
mentation are possible among this population.
It is important for adolescents, coaches, and parents to be aware of evidence‐based
recommendations regarding the safety and efficacy of creatine supplementation when
considering its use. Many misconceptions are present regarding creatine [81], and there‐
fore consumers should seek out expert advice regarding safe and informed use of creatine.
Readers are also directed to the most recently published Position Stand on creatine pub‐
lished by the International Society of Sports Nutrition [1] for a complete summary regard‐
ing the mechanisms of action, ergogenic benefits, safety, clinical applications and dosing
recommendations of creatine. In brief, the statements from the position stand below are
most pertinent to the focus of the current review article:








“Creatine monohydrate is the most effective ergogenic nutritional supplement cur‐
rently available to athletes with the intent of increasing high intensity exercise capac‐
ity and lean body mass during training.”
“Creatine monohydrate supplementation is not only safe, but has been reported to
have a number of therapeutic benefits in healthy and diseased populations ranging
from infants to the elderly. There is no compelling scientific evidence that the short‐
or long‐term use of creatine monohydrate (up to 30 g/day for 5 years) has any detri‐
mental effects on otherwise healthy individuals or among clinical populations who
may benefit from creatine supplementation.”
“If proper precautions and supervision are provided, creatine monohydrate supple‐
mentation in children and adolescent athletes is acceptable and may provide a nutri‐
tional alternative with a favorable safety profile to potentially dangerous anabolic
androgenic drugs. However, we recommend that creatine supplementation only be
considered for use by younger athletes who: (a) are involved in serious/competitive
supervised training; (b) are consuming a well‐balanced and performance‐enhancing
diet; (c) are knowledgeable about the appropriate use of creatine; and (d) do not ex‐
ceed recommended dosages.”
“Label advisories on creatine products that caution against usage by those under 18
years old, while perhaps intended to insulate their manufacturers from legal liability,
are likely unnecessary given the science supporting creatine’s safety, including in
children and adolescents. The quickest method of increasing muscle creatine stores
may be to consume ~0.3 g/kg/day of creatine monohydrate for 5–7‐days followed by
3–5 g/day thereafter to maintain elevated stores. Initially, ingesting smaller amounts
of creatine monohydrate (e.g., 3–5 g/day) will increase muscle creatine stores over a
3–4 week period, however, the initial performance effects of this method of supple‐
mentation are less supported.”
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